Albert Bourla

Albert Bourla is a Greek veterinarian and business executive who serves as the chairman and chief executive officer of the multinational pharmaceutical and biotechnology corporation Pfizer. Under his leadership, Pfizer rapidly developed one of the first COVID-19 vaccines in partnership with BioNTech, a pivotal achievement during the COVID-19 pandemic. Bourla has held numerous senior roles at Pfizer since joining the company in 1993, overseeing major divisions including its Innovative Health and Essential Health businesses before ascending to the top position.

Early life and education

Albert Bourla was born on October 21, 1961, in Thessaloniki, Greece, to a family of Sephardic Jewish descent. He completed his undergraduate studies in veterinary medicine at the Aristotle University of Thessaloniki, earning a Doctor of Veterinary Medicine degree. He subsequently pursued a Ph.D. in the biotechnology of reproduction at the University of Veterinary Medicine, Brno in the former Czechoslovakia. His early academic work focused on advanced reproductive technologies, laying a scientific foundation for his future career in the pharmaceutical industry.

Career at Pfizer

Bourla began his career at Pfizer in 1993 in the animal health division in Greece. He held positions of increasing responsibility across Europe and the United States, including roles in business development and general management. He served as president of Pfizer's Essential Health business, overseeing established medicines, and later as group president of the Innovative Health business, managing the company's biopharmaceutical portfolio. In 2018, he was appointed chief operating officer, overseeing the company's commercial strategy, manufacturing, and global supply chain before succeeding Ian Read as CEO in January 2019 and adding the chairman title later that year.

Leadership during the COVID-19 pandemic

Upon becoming CEO, Bourla initiated a significant restructuring of Pfizer, focusing the company on innovative science. His most defining leadership moment came with the outbreak of the COVID-19 pandemic. In March 2020, he committed Pfizer to developing a vaccine at unprecedented speed, entering a strategic partnership with the German biotech firm BioNTech. Bourla championed the mRNA technology platform and made the high-stakes decision to invest billions in manufacturing capacity before knowing if the vaccine, later named Comirnaty, would be successful. The vaccine received the first Emergency Use Authorization from the U.S. Food and Drug Administration in December 2020, marking a historic milestone in public health.

Awards and recognition

For his role in the pandemic response, Bourla has received numerous accolades. He was named the 2021 CEO of the Year by CNN Business and was included in *Time* magazine's list of the 100 Most Influential People of 2021. He received the Genesis Prize in 2022, often called the "Jewish Nobel," and the Global Citizen Award from the Atlantic Council. In 2023, he was honored with the Lasker-Bloomberg Public Service Award for his leadership in the development and equitable distribution of the COVID-19 vaccine.

Personal life

Bourla is married and has two children. He is a vocal advocate for science education and global health equity, often speaking on the importance of public-private partnerships. In his memoir, *Moonshot: Inside Pfizer's Nine-Month Race to Make the Impossible Possible*, he details the vaccine development effort. Bourla maintains strong ties to Greece and is involved with several philanthropic initiatives, including supporting the Jewish Museum of Thessaloniki and efforts to combat medical misinformation.

Category:1961 births Category:Living people Category:Greek chief executives Category:Greek veterinarians Category:Pfizer people